ArticleCureus2025
Trichilemmal Carcinoma in a Patient With Oculocutaneous Albinism.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unique occurrence of trichilemmal carcinoma in the scrotal skin of a giant panda: a pathological analysis.BMC veterinary research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trichilemmal carcinoma (TC) is a rare adnexal neoplasm derived from the outer sheath of the hair follicle. Despite its aggressive histological features, TC typically exhibits low-grade clinical behavior, with local recurrences being more common than metastasis. This case report describes a 47-year-old Hispanic female with oculocutaneous albinism and a history of numerous nonmelanoma skin cancers (NMSCs) who presented with an erythematous papule on her forearm. Histopathology revealed TC characterized by basaloid keratinocytes with clear cytoplasm and peripheral palisading and a high proliferation rate confirmed by Ki-67. Surgical excision with 1.0 cm margins was performed, and final histopathology showed no residual tumor. Concurrently, the patient was diagnosed with metastatic squamous cell carcinoma (SCC) and started on pembrolizumab. This case highlights the increased susceptibility of individuals with oculocutaneous albinism to multiple and varied skin malignancies, stressing the need for vigilant skin surveillance and a broad differential diagnosis in this population. The patient's history underscores the importance of early detection and intervention to manage and mitigate the risk of advanced skin cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.